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Abstract
Background: Major depressive disorder (MDD) is projected to rank second on a list of 15 major diseases in terms
of burden in 2030. The major contribution of MDD to disability and health care costs is largely due to its highly
recurrent nature. Accordingly, efforts to reduce the disabling effects of this chronic condition should shift to
preventing recurrence, especially in patients at high risk of recurrence. Given its high prevalence and the fact that
interventions are necessary during the remitted phase, new approaches are needed to prevent relapse in
depression.
Methods/design: The best established effective and available psychological intervention is cognitive therapy.
However, it is costly and not available for most patients. Therefore, we will compare the effectiveness and cost-
effectiveness of self-management supported by online CT accompanied by SMS based tele-monitoring of
depressive symptomatology, i.e. Mobile Cognitive Therapy (M-CT) versus treatment as us usual (TAU). Remitted
patients (n = 268) with at least two previous depressive episodes will be recruited and randomized over (1) M-CT
in addition to TAU versus (2) TAU alone, with follow-ups at 3, 12, and 24 months. Randomization will be stratified
for number of previous episodes and type of treatment as usual. Primary outcome is time until relapse/recurrence
over 24 months using DSM-IV-TR criteria as assessed by the Structured Clinical Interview for DSM-IV Axis I Disorders
(SCID). For the economic evaluation the balance between costs and health outcomes will be compared across
strategies using a societal perspective.
Discussion: Internet-based interventions might be helpful in empowering patients to become their own disease
managers in this lifelong recurrent disorder. This is, as far as we are aware of, the first study that examines the
(cost) effectiveness of an E-mental health program using SMS monitoring of symptoms with therapist support to
prevent relapse in remitted recurrently depressed patients.
Trial registration: Netherlands Trial Register (NTR): NTR2503
Background
Major depressive disorder (MDD) is projected to rank
second on a list of 15 major diseases in terms of burden
in 2030 [1]. The contribution of MDD to disability and
health care costs is largely due to its highly recurrent
nature [2,3]. Accordingly, efforts to reduce the disabling
effects of depression should shift to preventing recur-
rence, especially in patients at high risk of recurrence.
Current maintenance therapy is often labour intensive
involving collaboration among multiple health services
over long periods. This is costly and prone to
non-adherence to protocols on the part of health service
providers and non-compliance on the part of patients.
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become their own disease managers.
Cognitive therapy (CT) is an effective treatment of
MDD and an effective preventive treatment [4-6]. In a
multicenter RCT enrolling remitted recurrently
depressed patients, we evaluated the efficacy and cost-
effectiveness of a brief face-to-face CT added to treat-
ment as usual (TAU) compared with TAU alone [6]. In
line with other studies on CT, we found that CT was
effective (and cost-effective: Bockting CLH, Dijkgraaf
MGW, Hakaart-van Roijen L et al.: Cost-effectiveness of
relapse-prevention cognitive therapy in recurrent
depression: a two year study, submitted) in preventing
recurrences over a 2-year follow-up and even over 5.5
years [7], in patients with multiple previous episodes.
Given its high prevalence and the fact that interven-
tions are necessary during the remitted phase of this
life-long disease, new approaches are needed to prevent
relapse and recurrence in depression. This new
approach must not only be acceptable to remitted
patients, but also reach patients who often do not seek
treatment in this phase of the disease. Several advan-
tages have been noted of an e-mental health disease
management program [8,9]. First, SMS-based monitor-
ing on depression makes it easier for the patient and
therapist to detect relapse as early as possible. Second,
internet-based delivered cognitive therapy including
SMS based monitoring by making use of cell phones
(Mobile-CT) is mainly a self management intervention
in which patients create their own prevention of relapse
program. Third, patients can easily dose their own
amount of online therapist support in line with their
needs. Overall, therapist’s involvement may be reduced,
as has been reported in the internet based treatment of
acute depression [8]. Finally, this self-management
approach toward preventing relapse and recurrence in
depression can be used at home or at any venue of con-
venience to the patient. A recent meta-analysis [9]
revealed that internet based interventions seem to be
effective interventions for acute depression, especially
when the intervention is supported by therapist contact.
Trial objectives and Purpose
In this study, the addition of an internet based interven-
tion with automated tele-monitoring (Mobile-CT,
referred to as M-CT) to TAU, will be compared to
TAU alone in a sample size of 214 (2x107) recovered
patients. Alongside the randomized controlled trial, a
cost effectiveness analysis (from a societal perspective)
will be conducted.
It is hypothesized that adding M-CT is clinically
superior to treatment-as-usual alone (TAU) for prevent-
ing relapse and recurrence in depressive disorder. In
addition, we expect that the intervention dominates the
comparator condition in terms of cost-effectiveness.
Since co-morbidity with concurrent chronic somatic
illnesses, is defined by the American Psychiatric Associa-
tion [10] as a risk factor for future relapse and recur-
rence, differential response in this group of patients will
be examined explicitly. We will also conduct moderator
analysis to see if there are any baseline characteristics of
the participants that are prognostically relevant for
treatment response. Finally, we will conduct incremental
cost-benefit regression analysis to identify subgroups
where the intervention is particularly cost-effective.
Methods/Design
In this randomized controlled trial with a sample size of
268 participants (after accounting for 20% drop out,
M-CT: 107, TAU: 107) we compare an internet-supported
self-directed prevention of relapse program as part of a
SMS based monitoring versus treatment as usual (TAU).
This M-CT program is called Depression Free. The target
population is a group at elevated risk of relapse and recur-
rence as identified in several guidelines (e.g. NICE) [11,12]
that consumes a considerable amount of health care and
for whom initial benefits of antidepressants (AD) may be
wane off in the long run. Relapse rates rise with increasing
numbers of previous episodes up to 70% in 5 years [12]. In
our previous study, we observed up to 62% recurrences
within 2 years [13].
Randomization will be undertaken by an independent
researcher and will be stratified by the number of pre-
vious depressive episodes and type of care (i.e. care by a
general practitioner versus care in a mental health cen-
ter) will then be used for stratified randomization.
Thereafter our researchers receive the participant num-
ber and the automatically random generated condition
in the trial by email. For a Flow diagram of the assess-
ment methods see Figure 1.
We monitor the primary outcome (relapse) over a
period of 24 months. Assessments by trained assessors
who are blind to treatment allocation (and whose blind-
ness is checked within each assessment session) take
place directly after the start of the treatment at three
months, 12 and 24 months. For the research aims
focused on potential working mechanisms of M-CT we
added in between self-report assessments, i.e. baseline,
1.5 months and 3 months.
The interventions
M-CT-arm: This M-CT treatment builds on a previously
evaluated face to face intervention, i.e. Preventive Cogni-
tive Therapy (PCT) [14] and has been developed in colla-
boration Bockting & van Valen [15] with the Trimbos
Institute. The face to face PCT is an adapted type of cog-
nitive therapy for acute depression [16] and specifically
developed to prevent relapse in recurrent depression in
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regular CT, each PCT session follows a fixed structure,
with agenda setting, review of homework, explanation of
rationale of each session, and assignment of homework.
A manual describing the structure of the treatment and
interventions used is available [14]. The intervention pre-
vention program targets underlying cognitive vulnerabil-
ity factors, such as depressogenic assumptions. Unlike
CT for acutely depressed patients, PCT is not primarily
directed toward modifying negative thoughts. Instead, it
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Figure 1 Flow Diagram.
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dysfunctional attitudes, aided by a self-report question-
naire with examples of attitudes and specific techniques
such as the downward arrow technique. The focus of
treatment is then directed on changing these attitudes
using different cognitive techniques such as Socratic
questioning and identification of positive attitudes. More-
over, patients are encouraged to practice with alternative
attitudes in the final sessions. Remitted patients with a
history of recurrences have an inability to retrieve specific
memories from the past and this is associated with
impaired problem-solving skills [e.g. 17], long-term
course of depressive disorders [18] and difficulties in
recovering from depression. Part of the treatment is
keeping a diary of positive experiences in order to
enhance specific memories of positive experiences,
instead of retaining overly general memories. Further
specific relapse/recurrence prevention strategies are for-
mulated in the last three sections of the M-CT resulting
in a personal prevention plan.
The M-CT intervention is based on the above
described face to face PCT. It is offered over the inter-
net in a series of 8 well-structured modules with online
therapist contact (with a maximum of 4 telephone ses-
sions) and by SMS. Each module includes assignments
with automatically generated feedback. In addition, films
can be activated by the participant to explain more
about specific topics. Each module can be completed in
approximately 20 minutes, not counting the time
required to complete additional assignments. If all
assignments are completed, E-personal prevention book
will be automatically generated that can be of help in
case of relapse of lowered mood. Automated checks will
be conducted to ascertain that participants have not
only completed modules, but also understood them cor-
rectly, before they can move on to the next. When parti-
cipants do not log in on the intervention’s website they
will receive friendly reminders by SMS or mail to pro-
ceed with the intervention.
Depression-related outcomes (changes in mood) will
be monitored with help of SMS (or by email if
requested). To this end, participants periodically receive
SMS messages in which they will be asked to rate their
mood. Participants have to answer by sending a message
back consisting of a number with which they rate their
mood. When depressed mood is present and appears to
persist, then the frequency of messages is increased and
other depressive symptoms are monitored also using a
web-based self-report assessment (IDS-R) [19]. In case
there is indeed an indication for a depressive episode,
participants will be interviewed using the SCID [20] and
the Hamilton Rating Scale for Depression (HRSD) [21].
This allows for the early detection of possible depression
onset. In that scenario, participants receive advice and
are encouraged to return to the website where they can
find ‘prescribed’ modules. Hopefully, this offers them
the opportunity to better cope with lowered moods.
The intervention is designed to be easily accessible,
acceptable and as non-intrusive as possible, while at the
same time allowing for tele-monitoring of health related
outcomes over the time-span of several years. The
web-based intervention has been developed by the
Trimbos Institute, the University of Groningen, Cross-
Over Consultancy and their partners.
Treatment As Usual
The intervention will be compared to treatment as usual
(TAU). In this context TAU is fairly heterogeneous: it
typically consists of antidepressant (AD) maintenance
medication in primary and secondary care, counseling
or face-to-face PCT in secondary care, but often there is
no treatment at all. To compare the intervention with
TAU is relevant from a public health perspective: it
would help to demonstrate the intervention’s added
v a l u eo v e ra n da b o v eT A U .W ew i l ln o ti n t e r v e n ew i t h
TAU, but monitor TAU using a health service receipt
interview, the TIC-P [22]. We will assess compliance
and adherence to AD use, but also the use of the M-CT
program.
Sample size
With 107 in M-CT versus in TAU 107 participants per
condition the trial will be powered to detect a differ-
ence of 20% in the cumulative incidence rate of
relapse/recurrence with a 2 year follow-up in a 2-tailed
test at the conventional alpha level of 0.05 and a
power of (1-beta) = 0.80, while conservatively assuming
that relapse/recurrence will occur in 50% of the cases.
Allowing for a drop-out of 20% we need to include
268 participants at baseline.
Referral and recruitment
Patients will be recruited by media (announcements,
banners placed in various related websites, media atten-
tion in interviews), referral by general practitioners and
mental health services. Patients with concurrent chronic
somatic illnesses will be recruited by targeted marketing
strategies (e.g. banners on website targeted on patients
with chronic somatic illnesses, posters in hospitals) and
specific recruitment at general practitioners.
Inclusion criteria
We include recovered patients with a history of at least
two previous depressive episodes in the past five years.
T h el a s te p i s o d eh a st ob ea tl e a s t2m o n t h sa n dn o
longer than 2 years ago. The last episode has to be at
least 2 months and no longer than 2 years ago and a
current score of ≤10 on the HRSD [21; in line with
other prevention studies, e.g. 5-6]. No restriction with
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rent chronic somatic illness is defined as risk factor for
relapse and recurrence, [APA, 10]. Consenting partici-
pants need to be fluent in Dutch and have access to the
internet.
Exclusion criteria
Exclusion criteria are: current mania or hypomania or a
history of bipolar illness, any psychotic disorder (current
and previous), alcohol or drug misuse, predominant
anxiety disorder.
Assessment of Eligibility and Baseline Measures
Informed consent
We inform patients about the study before they come
into the study in two ways. First, by informing the
patient through a therapist or a general practitioner
(GP). If a therapist/GP wants to inform the patient
himself, the patient then receives the information
via the therapist/GP and is given a letter containing
all the information. If the patient is interested in
participating, then the participant will contact the
researcher. Subsequently, the researcher checks that
the participant understands all aspects of the trial. If
the participant agrees to enter the trial, she completes
a copy of the consent form and sends it to the
researcher.
The second procedure we use is by directly informing
the patient. Participants than initiate that contact with
the researcher themselves (mostly informed by media/
websites or by their former therapist/GP with a letter,
by advertisements or interviews). Subsequently, the
researcher informs the participant, the participant
receives the information in a letter with all the informa-
tion in it. If the participant is still interested in partici-
pating then the researcher checks that the participant
understands all aspects of the trial. If they agree to
enter the trial, they complete a copy of the consent
form and send it to the researcher. We remind partici-
pants that they can withdraw from the trial at any time
and that this has no consequences for their treatment
as usual.
We ask consenting participants to provide information
about their socio-demographic background and assess
their eligibility in more detail using semi-structured clin-
ical interviews (SCID-I, by telephone) and self-
completed questionnaires (web-based). The researchers
assess current and past diagnostic status using the
Structured Clinical Interview for DSM IV (SCID) [20]
and the Hamilton Rating Scale for Depression (HRSD)
[21]. They ask participants to describe past and current
treatments for depression and use of antidepressants. If
participants meet all inclusion and none of the exclusion
criteria for the study, they enter the study.
Withdrawal
Participants can withdraw from treatment or from the
study at any time.
Safety monitoring and reporting
The trial protocol has been approved by an independent
medical ethics committee (METIGG). Eligible people
will only be included as participants in the trial after
informed consent has been obtained.
We record and report suspected serious adverse
events to the Multi-center Ethic Committee (METIGG)
according to their individual guidelines.
Baseline assessment
For the baseline assessment we ask participants them-
selves to complete the web-based self-report question-
naires in two packages, i.e. explicit and implicit
measures. The first part with assessments starting
directly within a week, the second part containing impli-
cit measures will be offered within 2 days after comple-
tion of self-report assessments measures. The following
self-report measures will be used: the Inventory of
Depressive Symptomatology, IDS-SR [19], Nemesis
Somatic illnesses list [23], negative life events
(Life events questionnaire, LGV) [24], self-esteem
(Self-esteem Questionnaire) [25], personality pathology
(Personality Diagnostic Questionnaire, PDQ-4) [26],
everyday problems (EPCL) [27], hypomania (HCL-32)
[28], direct and indirect costs (TIC-P) [22] and Medica-
tion Adherence Questionnaire (MAQ) [29], a measure
of general quality of life (Euro-QOL EQ-5D) [30], and
rumination (Ruminative Responses Subscale of the
Response Styles Questionnaire RSQ) [31], dysfunctional
attitudes (Dysfunctional Attitudes Scale, DAS) [32],
LEIDS [33], acceptance (Acceptance and Action
Questionnaire, AAQ) [34], coping (Utrecht Coping List,
UCL) [35], Mastery 7 [36]. After 6 weeks this set will be
repeated with the exception of the TIC-P, LGV, PDQ,
MAQ EQ-5 D and Nemesis Somatic illnesses list.
During follow-up every three months the following self-
report assessments will be repeated: IDS-SR, HCL-32,
TIC-P, EPCL, Mastery7 and EQ-5 D will be adminis-
tered. For a complete overview of the assessments see
Table 1. Participants in the M-CT group will also
answer questions of the Dutch version of the Credibility
and expectancy questionnaire [37,38] before and after
finishing M-CT.
Outcome measures
For an overview of the assessments at baseline, in
between- and post treatment and follow up assessments
see Table 1.
Primary outcome
Primary outcome is time until relapse or recurrence of
depression in the experimental group relative to the
Bockting et al. BMC Psychiatry 2011, 11:12
http://www.biomedcentral.com/1471-244X/11/12
Page 5 of 9control group over 24 months using DSM-IV-R criteria
as assessed by the SCID at 3 months, 12 months and
24 months [20]. Co-morbidity with concurrent chronic
somatic illnesses will be assessed using the NEMISIS
somatic illnesses list [23]. Secondary outcome is
symptom severity as measured with the Inventory of
Depressive Symptomatology (IDS-R) [19] and number of
relapses as assessed by the SCID [20]. For the economic
evaluation we will use the EuroQoL (EQ-5D) to obtain a
generic quality of life related outcome [30]. Cost data
related to health care uptake will be sampled using the
TIC-P [22]. Cost data stemming from production losses
due to absenteeism and working less efficiently while at
work will be collected with the specific modules from
the TIC-P [22].
Moderators and Mediators
For potential moderators (illness related, stress-related
and cognitive-related) predictors and mediators the fol-
lowing self-report measures will be used at baseline, at
1,5 and at 3 months (internet based): Inventory of
Depression Symptomatology (IDS-SR every 3 months)
[19], Dysfunctional Attitude Scale, (DAS-A) [32], LEIDS
[33], Everyday Problem Checklist (EPCL) [27], Negative
Life Events Questionnaire [24] and to assess nonadher-
ence to AD with the Medication Adherence Question-
naire (MAQ) [29], Mastery7 [36]. To enable calculating
quality adjusted life years required for the economic
evaluation the EQ5 D will be administered every
3 months [30]. To test whether M-CT affects implicit
attitudes and attentional bias differentially and whether
residual difficulty to disengage and residual dysfunc-
tional implicit attitudes are related to the return of
depressive symptoms, an web-based Implicit Association
Test (IAT) [39] will be used to assess implicit attitudes.
A web-based rapid serial visual presentation (RSVP) [40]
task will be used to assess the difficulty to disengage
from negative information. Difficulty to disengage will
be indexed by the magnitude of the attentional blink
when negative self descriptors are presented as the first
target and neutral words as the second. For an overview
of the assessments at baseline, in between- and post
treatment and follow up assessments see Table 1.
Analysis
Cox regression analysis (survival analysis) will be per-
formed, including as covariates the stratification
Table 1 Overview of assessments
Measure Description T0 T1 T2 T3 T4 T5 T6 T7 T8 T9*
Interviews
SCID-I DSM-IV-TR Axis I disorders + + + +
HDRS Depressive symptoms and severity + + + +
CEQ, only M-CT group Credibility/expectancy questionnaire + +
Implicit computer assignments
IAT Implicit associations + +
RSVP Ability to disengage from negative information + +
Self report measures
IDS-SR Depressive symptoms + + + + + + + + + +
RSQ Ruminative responses + + + + +
EQ-5D Quality of life + + + + + + + + +
DAS Dysfunctional Attitudes + + + + +
AAQ Experiential acceptance and avoidance + + + + +
UCL Coping + + + + +
LGV Life-events + + + +
Self-esteem Self-esteem
PDQ-4+ Personality + + +
Nemesis Somatic illnesses list List of somatic disorders + + +
EPCL Everyday problem list + + + + + + + + + +
HCL-32 Hypomania + + + + + + + + + +
TIC-P including MAQ** Direct/indirect costs + ++++++++
LEIDS Dysfunctional attitudes + + + + +
Mastery 7 Mastery + + + + + + + + + +
*T0 = Baseline, T1 = +1,5 month, T2 = 3 months, T3 = 6 months, T4 = 9 months, T5 = 12 months, T6 = 15 months, T7 = 18 months, T8 = 21 months, T9 = 24 months.
**MAQ: Medication Adherence questionnaire.
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of previous episodes and type of care (primary/second-
ary/no care). Analysis will be conducted by intention to
treat, including all subjects randomized in the study,
and per protocol, including only subjects satisfying pro-
tocol. Statistical significance will be set at P < .05.
Mixed-model analysis of variance (ANOVA) will be
used for the other variables, including baseline values of
the dependent variable as a covariate in all analyses. We
shall use implicit and explicit cognitive measures and
stress measures (daily hassles) to explore the extent to
which they mediate relapse and recurrence during treat-
ment and follow up.
For the economic evaluation the balance between
costs and health outcomes will be compared across stra-
tegies using a societal perspective. Primary outcome
measure: the number of depression-free days. Both
short-term and long-term consequences will be com-
pared. Additionally, Quality Adjusted Life Years will be
used as outcome (see also Table 1).
Discussion
Given the high prevalence of MDD and its recurrent
character new minimal interventions are needed to
prevent relapse and recurrence in depression. Inter-
net-based interventions might be helpful in empower-
ing patients to become their own disease managers in
this lifelong recurrent disorder. This is, as far as we
are aware of, the first study that examines the (cost)
effectiveness of an E mental health program using
SMS and mail monitoring of symptoms with therapist
support to prevent relapse in remitted recurrently
depressed patients. Attrition is a very common phe-
nomenon in internet-based interventions, hopefully
the therapist support in this intervention will reduce
attrition rates, as suggested in the meta-analysis of
Spek et al [9]. In addition, mediation variables will be
examined to get more insight into the most effective
ingredients of the M-CT used. This might lead to
insights that will lead to the development of more
targeted interventions.
In summary, given the highly recurrent nature of
MDD, new minimal interventions should be developed
and evaluated to prevent recurrence in patients at high
risk of recurrence, i.e. patients with multiple prior
episodes. Internet based intervention including SMS
based monitoring might be promising in disrupting
the rhythm of depression, as will be examined in
this study. This combination of self management-
monitoring and self help could be an easily implemen-
ted and potential cost effective part of a broader
disease-management program of a chronic (recurrent)
illness, i.e. MDD.
Appendix 1: Statistical Analysis Plan
All analysis will be conducted in agreement with the
intention to treat principle as per the CONSORT state-
ment. Cox regression analysis will be performed, includ-
ing as covariates the stratification variables that will be
used in randomization, i.e.: number of previous epi-
sodes, type of care (no/primary/secondary). Statistical
significance will be set at P < .05. When adding the
intervention to TAU is superior then the relapse/recur-
rence rate in this condition should be smaller than in
the comparator condition (TAU alone). Therefore, we
will obtain cumulative relapse/recurrence hazard rate
ratios (Hr’s). To gauge the robustness of the outcomes,
the above analyses will be repeated under a completers-
only framework.
Since co-morbidity with a concurrent chronic
somatic illness for which medical attention is received
is defined by the American Psychiatric Association as
risk factor for future relapse and recurrence [10], dif-
ferential response in this group of patients will be
examined explicitly. Subgroups that show particularly
good response to the intervention will be identified by
regressing SCID depression severity on the interaction
term of treatment and clinical characteristics of the
participants as measured at baseline. Examples of other
characteristics are number of previous depressive epi-
sodes, age at which the first depression occurred, con-
current personality disorders, concurrent anxiety
disorder, experienced life events, some demographic
characteristics (like gender) and sense of mastery. In
addition, moderator analysis will also be conducted for
demographic variables such as gender, age, educational
level, partner status, employment status. These vari-
ables have been shown to be of prognostic value in
depressive disorder. The same set of predictor variables
will also be used in an incremental net benefit regres-
sion analysis to addresses the research question in
what groups the intervention is likely to be particularly
cost-effective.
The economic evaluation will be conducted both as a
cost-effectiveness analysis with depression-free survival
time as the clinical end term, and as a cost-utility ana-
lysis with incremental costs per quality adjusted life
years (QALYs) gained as the clinical endpoint. For the
latter, health-related quality of life, will be assessed
with help of the EQ-5 D at baseline and follow-ups.
Direct medical and direct non-medical cost data are
collected with the TIC-P [22], a widely used health
service receipt interview in economic evaluations. Unit
resource use (GP visits, hospital days, etc.) will be mul-
tiplied by their appropriate integral cost prices [41].
Indirect non-medical cost data related to production
losses through work loss days and work cutback days
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For the economic evaluation use will be made of the
pertinent guidelines [42-44]. In other words, analyses
will be conducted in agreement with the intention-to-
treat principle, the societal perspective will be taken
encompassing intervention costs, direct medical costs,
direct non-medical costs and indirect costs. The latter
will encompass production losses due to absenteeism
and due to working less efficient while at work. Pro-
duction losses will be economically valuated using the
friction cost method [45] as per the Dutch guideline
[42]. The time horizon will be set at two years and
therefore costs and effects will be discounted. Costs
and effects will be analyzed simultaneously, incremen-
tal cost-effectiveness ratios (ICERs) will be calculated
and placed within 95% confidence intervals, 2,500
bootstrap replications of the ICERs will be projected
on a cost-effectiveness plane, ICER acceptability curves
will be plotted against different willingness-to-pay ceil-
ings and sensitivity analysis will be conducted as a
matter of course focusing on uncertainty in the
analysis.
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